Does the use of a special (blue-green) colored light for removing bladder tumours help in increasing the rate amount of tumour detected in cases of bladder cancer ?

The impact of narrow band imaging (NBI) in the detection of bladder tumour in transitional cell carcinoma of the bladder: A randomized crossover controlled trial from a tertiary care centre in India. - NBTECTT TRIAL

Status

Recruiting

Phases

Phase 1Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2015/03/005626

Enrollment

190

Registered

2015-03-12

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Transitional Cell Carcinoma Bladder

Interventions

Intervention1: Narrow band imaging (Olympus system): NBI, an optical image enhancement technique, is based on the fact that the depth of light penetrating into the urothelium increases with increasing

Eligibility

Inclusion criteria

Inclusion criteria: All patients who undergo Trans - urethral resection of bladder tumour (TURBT) in CMC Vellore from August 2013 to December 2014. New tumours and recurrent tumours (single or multiple tumours , largest tumour less than or equal to 5 cms in size) will both be included. Diagnosis of bladder tumours will be made on the basis of cystoscopic findings, imaging Ultrasonography (USG), Intravenous pyelogram (IVP) or Computerized tomography (CT) or urine cytology. Patients should be fit for anesthesia as decided by anesthetists.

Exclusion criteria

Exclusion criteria: Refused to consent Size of tumour >5 cm Other modality of treatment (Radiotherapy ) Not fit for anesthesia

Design outcomes

Primary

Measure	Time frame
1. Number of tumours detected by either modality: The pathologist will report the presence of malignancy, if detected, in both samples. The extra number of lesions, (tumours/ CIS), if reported, will be correlated to the type of light source used and will be used for statistical analysis. Negative reports will also be noted. 2.Completeness of resectionTimepoint: The outcome will be assessed at the end of recruitment of all the patients required to complete the sample size (95 in each arm).	—

Measure

Time frame

1. Number of tumours detected by either modality: The pathologist will report the presence of malignancy, if detected, in both samples. The extra number of lesions, (tumours/ CIS), if reported, will be correlated to the type of light source used and will be used for statistical analysis. Negative reports will also be noted. 2.Completeness of resectionTimepoint: The outcome will be assessed at the end of recruitment of all the patients required to complete the sample size (95 in each arm).

—

Secondary

Measure	Time frame
NILTimepoint: NIL	—

Countries

India

Contacts

Public ContactDr Partho Mukherjee

Christian Medical College, Vellore

antonydevasia@cmcvellore.ac.in

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026